Description

Saxagliptin Tablets 5mg are formulated for research use to investigate DPP-4 inhibition, glucose metabolism, and type 2 diabetes models. Saxagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor, is widely studied for its effect on enhancing incretin hormone activity and improving glycemic control in experimental models.

This product is manufactured by Jiangsu Hengrui Medicine Co., Ltd., a leading pharmaceutical manufacturer, and is packaged as 28 tablets (4 blister packs × 7 tablets). For non-clinical use only.

Saxagliptin Tablets Product Specifications

• Product Name: Saxagliptin Tablets

• Active Ingredient: Saxagliptin

• Form: Oral tablet

• Strength: 5 mg per tablet

• Pack Size: 28 tablets (4 blisters × 7 tablets)

• CAS Number: 361442-04-8

• Molecular Formula: C18H25N3O2·HCl

• Molecular Weight: 351.87 g/mol (base)

• Drug Approval Number: H20203537

• CN Drug Code: 86901444001205

• Manufacturer: Jiangsu Hengrui Medicine Co., Ltd.

• Barcode: 6924647726366

• Usage: For laboratory research use only

Saxagliptin Tablets Mechanism of Action

Saxagliptin inhibits the DPP-4 enzyme, which is responsible for the degradation of incretin hormones. By blocking DPP-4, Saxagliptin prolongs GLP-1 and GIP activity, leading to enhanced insulin secretion and suppressed glucagon release in glucose-dependent models.

Saxagliptin Tablets Known Side Effects

Although not for clinical use, in pharmacological studies Saxagliptin has been associated with:

• Nasopharyngitis

• Headache

• Hypoglycemia (especially in combination studies)

• Potential renal function impact in long-term use

These effects are cited from research literature and do not imply human suitability.

Disclaimer

This product is strictly intended for laboratory and scientific research. It is not approved for human use, clinical diagnosis, or treatment. Use only under appropriate institutional or regulatory oversight.